S2-E8.2 – Previewing NASH-TAG 2021: Day Two
Stephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell and Roger Green the issues that each of them anticipate most eagerly
February 27, 2021
Stephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell and Roger Green the issues that each of them anticipate most eagerly
Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12
Three experience NASH trial site execs identify at least 11 specific things to consider when designing your trial protocols
NEW CONTENT: Suneil Hosmane joins Roger Green to discuss why he found the FDA Webcast so encouraging for liquid biomarkers
The Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of theFDA Webcast that centered on drug development and clinical trial strategies
The Surfers discuss the Global Liver Institute’s campaign to educate and motivate key stakeholder groups on the value of non-invasive liver testing.
The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.
